Literature DB >> 27369650

Efficacy of denosumab combined with bDMARDs on radiographic progression in rheumatoid arthritis.

Tetsuo Hasegawa1, Yuko Kaneko2, Keisuke Izumi2, Tsutomu Takeuchi2.   

Abstract

Entities:  

Keywords:  Biologic agent; Denosumab; Radiographic progression; Rheumatoid arthritis

Mesh：

Substances：

Year:  2016        PMID： 27369650     DOI： 10.1016/j.jbspin.2016.05.010

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN： 1297-319X            Impact factor:   4.929


× No keyword cloud information.
  16 in total

Review 1.  Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature.

Authors:  Gonçalo Boleto; Moustapha Dramé; Isabelle Lambrecht; Jean-Paul Eschard; Jean-Hugues Salmon
Journal:  Clin Rheumatol       Date:  2017-07-01       Impact factor: 2.980

Review 2.  RANKL as a therapeutic target of rheumatoid arthritis.

Authors:  Sakae Tanaka; Yoshiya Tanaka
Journal:  J Bone Miner Metab       Date:  2020-10-18       Impact factor: 2.626

Review 3.  Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.

Authors:  Yahui Grace Chiu; Christopher T Ritchlin
Journal:  Expert Opin Biol Ther       Date:  2016-11-30       Impact factor: 4.388

4.  Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.

Authors:  K Ebina; M Hirao; J Hashimoto; H Matsuoka; T Iwahashi; R Chijimatsu; Y Etani; G Okamura; A Miyama; H Yoshikawa
Journal:  Osteoporos Int       Date:  2018-03-24       Impact factor: 4.507

5.  Role of LIGHT in the pathogenesis of joint destruction in rheumatoid arthritis.

Authors:  Afsie Sabokbar; Sara Afrough; David J Mahoney; Yoshinobu Uchihara; Catherine Swales; Nicholas A Athanasou
Journal:  World J Exp Med       Date:  2017-05-20

6.  Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis.

Authors:  Takako Suzuki; Yukio Nakamura; Hiroyuki Kato
Journal:  Ther Clin Risk Manag       Date:  2018-03-01       Impact factor: 2.423

7.  Imaging the Bone-Immune Cell Interaction in Bone Destruction.

Authors:  Tetsuo Hasegawa; Junichi Kikuta; Masaru Ishii
Journal:  Front Immunol       Date:  2019-03-26       Impact factor: 7.561

Review 8.  RANKL is a therapeutic target of bone destruction in rheumatoid arthritis.

Authors:  Sakae Tanaka
Journal:  F1000Res       Date:  2019-04-23

9.  Predictors of denosumab efficacy in treating osteoporosis in patients with rheumatoid arthritis: a Japanese multicenter study.

Authors:  Kyosuke Hattori; Yuji Hirano; Yasuhide Kanayama; Nobunori Takahashi; Naoki Ishiguro; Toshihisa Kojima
Journal:  Nagoya J Med Sci       Date:  2019-11       Impact factor: 1.131

10.  Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1.

Authors:  Tetsuo Hasegawa; Junichi Kikuta; Takao Sudo; Yoshinobu Matsuura; Takahiro Matsui; Szandor Simmons; Kosuke Ebina; Makoto Hirao; Daisuke Okuzaki; Yuichi Yoshida; Atsushi Hirao; Vladimir V Kalinichenko; Kunihiro Yamaoka; Tsutomu Takeuchi; Masaru Ishii
Journal:  Nat Immunol       Date:  2019-11-18       Impact factor: 25.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.